- Home
- HBI vs HCM Comparison
HBI vs HCM Comparison
Compare HBI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBI
- HCM
- Stock Information
- Founded
- HBI 1901
- HCM 2000
- Country
- HBI United States
- HCM Hong Kong
- Employees
- HBI N/A
- HCM N/A
- Industry
- HBI Clothing/Shoe/Accessory Stores
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- HBI Consumer Discretionary
- HCM Health Care
- Exchange
- HBI Nasdaq
- HCM Nasdaq
- Market Cap
- HBI 2.4B
- HCM 2.6B
- IPO Year
- HBI 2006
- HCM N/A
- Fundamental
- Price
- HBI $6.93
- HCM $16.01
- Analyst Decision
- HBI Buy
- HCM Sell
- Analyst Count
- HBI 4
- HCM 1
- Target Price
- HBI $6.50
- HCM $13.75
- AVG Volume (30 Days)
- HBI 6.6M
- HCM 56.9K
- Earning Date
- HBI 11-06-2025
- HCM 08-07-2025
- Dividend Yield
- HBI N/A
- HCM N/A
- EPS Growth
- HBI N/A
- HCM N/A
- EPS
- HBI 0.25
- HCM 0.53
- Revenue
- HBI $3,540,309,000.00
- HCM $602,197,000.00
- Revenue This Year
- HBI $1.61
- HCM N/A
- Revenue Next Year
- HBI N/A
- HCM $15.49
- P/E Ratio
- HBI $14.44
- HCM $5.91
- Revenue Growth
- HBI 2.95
- HCM N/A
- 52 Week Low
- HBI $3.96
- HCM $11.51
- 52 Week High
- HBI $9.10
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- HBI 74.68
- HCM 48.16
- Support Level
- HBI $6.44
- HCM $17.19
- Resistance Level
- HBI $7.05
- HCM $16.35
- Average True Range (ATR)
- HBI 0.15
- HCM 0.29
- MACD
- HBI 0.02
- HCM -0.01
- Stochastic Oscillator
- HBI 85.19
- HCM 21.74
About HBI Hanesbrands Inc.
Hanesbrands manufactures basic and athletic apparel under brands including Hanes, Playtex, Maidenform, Bali, Berlei, and Bonds. The company sells wholesale to discount, midmarket, and department store retailers as well as direct to consumers through stores and e-commerce. Hanesbrands is vertically integrated, as it produces nearly 75% of its products in company-controlled factories in more than three dozen nations. Hanesbrands distributes products in the Americas and Asia-Pacific. The company was founded in 1901 and is based in Winston-Salem, North Carolina. Hanesbrands has agreed to be acquired by Canadian rival Gildan.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.